Correction to the Methods: Center Subfield Diameter Unit in the Aflibercept 8 mg PULSAR Analysis

October 1, 2026

Jama Ophthalmology

Overview

An online correction to the PULSAR post hoc analysis of aflibercept 8 mg in polypoidal choroidal vasculopathy changed the center subfield diameter unit in the Methods section from 1 cm to 1 mm. The correction notice reports this unit amendment.

Background

Optical coherence tomography analyses use the macular center subfield to assess retinal anatomy. The supplied measurement context identifies the ETDRS center subfield as a 1-mm-diameter circle centered on the fovea, consistent with the corrected unit. The underlying article is a post hoc analysis of participants with polypoidal choroidal vasculopathy from the phase 3 PULSAR randomized clinical trial. Accurate reporting of measurement units is important for interpreting imaging methods and results.

Data Highlights

Item	Reported information
Correction	Center subfield diameter unit changed from 1 cm to 1 mm in the Methods section.
Original investigation	Online December 18, 2025; subsequently published in the February 2026 issue.
Related PULSAR PCV post hoc analysis at week 48	BCVA change: +9.5 letters (8 mg every 12 weeks), +8.4 (8 mg every 16 weeks), and +9.1 (2 mg every 8 weeks).
Central subfield thickness change at week 48	−159 µm, −152 µm, and −161 µm, respectively.
Eyes without polypoidal lesions among week-48 completers	37%, 47%, and 38%, respectively.

Key Findings

The correction changed the center subfield diameter unit in the Methods from 1 cm to 1 mm.
The corrected article is the post hoc PULSAR analysis of aflibercept 8 mg in polypoidal choroidal vasculopathy, published online December 18, 2025, and in the February 2026 issue.
The supplied measurement context describes the ETDRS center subfield as a 1-mm-diameter circle centered on the fovea.
In the related week-48 PCV analysis, least-squares mean BCVA changes were +9.5, +8.4, and +9.1 ETDRS letters for aflibercept 8 mg every 12 weeks, 8 mg every 16 weeks, and 2 mg every 8 weeks, respectively.
Central subfield thickness decreased by 159, 152, and 161 µm, respectively; polypoidal lesions were absent in 37%, 47%, and 38% of eyes among week-48 completers.
The supplied correction notice identifies a Methods unit amendment and does not describe changes to the trial findings.

Clinical Implications

When interpreting the corrected Methods, the center subfield diameter should be read as 1 mm, not 1 cm. The correction notice does not report a change to the PULSAR analysis results.

Conclusion

The online correction resolves the center subfield diameter unit in the PULSAR PCV analysis, replacing 1 cm with 1 mm. The related week-48 outcomes are reported separately as descriptive post hoc findings.